Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: Association with a change to an aggressive clinical course [10]

Blood

Volumn 100, Issue 3, 2002, Pages 1106-

  Chang, Chung Che ^a   Cleveland, Ronald P ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN;

ANTIGEN EXPRESSION; B CELL LEUKEMIA; BONE MARROW CELL; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; HUMAN; LETTER; LEUKEMIA; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS;

EID: 0036683379     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1287     Document Type: Letter

References (10)

1. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia
2. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease
3. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia
4. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
5. Discordant immunophenotype of chronic B-cell lymphoproliferative disorders in simultaneous specimens from bone marrow and peripheral sites
6. Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia
7. Myelomonocytic associated antigens in early B-chronic lymphocytic leukemia correlate with disease activity
8. Expression of myelomonocytic antigens on chronic lymphocytic leukemia B cells
9. Myelomonocytic antigens in B-cell chronic lymphocytic leukemia
10. Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome